| アブストラクト | PURPOSE: Fluoropyrimidines are anticancer drugs and can cause hyperammonemia both intravenously and orally. Renal dysfunction may interact with fluoropyrimidine to cause hyperammonemia. We performed quantitative analyses of hyperammonemia using a spontaneous report database to examine the frequency of intravenously and orally administered fluoropyrimidine, the reported frequency of fluoropyrimidine-related regimens, and fluoropyrimidine's interactions with chronic kidney disease (CKD). METHODS: This study used data collected between April 2004 and March 2020 from the Japanese Adverse Drug Event Report database. The reporting odds ratio (ROR) of hyperammonemia was calculated for each fluoropyrimidine drug and was adjusted for age and sex. Heatmaps depicting the use of anticancer agents in patients with hyperammonemia were drawn. The interactions between CKD and the fluoropyrimidines were also calculated. These analyses were performed using multiple logistic regression. RESULTS: Hyperammonemia was observed in 861 of the 641,736 adverse events reports. Fluorouracil was the most frequent drug associated with hyperammonemia (389 cases). The ROR of hyperammonemia was 32.5 (95% CI 28.3-37.2) for intravenously administered fluorouracil, 4.7 (95% CI 3.3-6.6) for orally administered capecitabine, 1.9 (95% CI 0.87-4.3) for tegafur/uracil, and 2.2 (95% CI 1.5-3.2) for orally administered tegafur/gimeracil/oteracil. Calcium levofolinate, oxaliplatin, bevacizumab, and irinotecan were the most frequently reported agents in cases of hyperammonemia with intravenously administered fluorouracil. The coefficient of the interaction term between CKD and fluoropyrimidines was 1.12 (95% CI 1.09-1.16). CONCLUSION: Hyperammonemia cases were more likely to be reported with intravenous fluorouracil than orally administered fluoropyrimidines. Fluoropyrimidines might interact with CKD in hyperammonemia cases. |
|---|
| ジャーナル名 | Cancer chemotherapy and pharmacology |
|---|
| Pubmed追加日 | 2023/5/19 |
|---|
| 投稿者 | Oura, Mitsuaki; Oguro, Fumiya; Agatsuma, Nobukazu; Imamaki, Hirotaka; Nishikawa, Yoshitaka |
|---|
| 組織名 | Department of Internal Medicine, Takeda General Hospital, Fukushima, Japan.;Department of Internal Medicine, Hirata Central Hospital, Fukushima, Japan.;Department of Gastroenterology and Hepatology, Kyoto University Graduate School;of Medicine, Kyoto, Japan.;Department of Nephrology, Hirakata Kohsai Hospital, Osaka, Japan.;Department of Health Informatics, Kyoto University School of Public Health,;Yoshidakonoecho, Sakyo-ku, Kyoto, 606-8501, Japan. ynishikawa-tky@umin.ac.jp. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37204512/ |
|---|
